Antimicrobial Resistance (AMR) remains a growing and concerning global challenge, despite decades of concerted effort. We’ve tried raising the alarm with terrifying statistics and compelling economic arguments, yet AMR continues to be overshadowed by other priorities. How do we move forward to secure the commitment and action needed to address AMR effectively?
This dynamic keynote session will explore key milestones in understanding, preventing, and managing AMR. The discussion will offer the latest insights on where we stand, address what is holding back progress, and showcase successful interventions. In the wake of the United Nations (UN) High-Level Meeting on AMR, this session will also address persistent challenges, including the slow pace of new drug development, inadequate regulatory frameworks, and the need for global coordination.
Ultimately, this session seeks to inspire the World Health Summit (WHS) audience with greater urgency, alignment, and ambition to bring commitments and goals for AMR to fruition from a policy and systems perspective. By examining both achievements and obstacles, this session aims to foster collective action to mitigate AMR's impact on global health. Join us in navigating the complex landscape of AMR, celebrate progress, and address the roadblocks that remain.
Hosts:
Federal Ministry of Health of Germany (BMG)
Moderators:
Latifat Okara
Economist Impact | Principal for Health Policy and Insights | United States of America
Speakers:
Dr. Muna Abu Sin
Federal Ministry of Health (BMG) | Ambassador on Antimicrobial Resistance | Germany
Dr. Abdullah Algwizani
Public Health Authority | CEO | Saudi Arabia
Prof. Dame Sally Davies
UK Special Envoy on Antimicrobial Resistance | United Kingdom
Dr. Arshnee Moodley
CGIAR | Antimicrobial Resistance Hub | Lead | Kenya
Dr. David Reddy
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Director-General | Switzerland
Antimicrobial Resistance (AMR) remains a growing and concerning global challenge, despite decades of concerted effort. We’ve tried raising the alarm with terrifying statistics and compelling economic arguments, yet AMR continues to be overshadowed by other priorities. How do we move forward to secure the commitment and action needed to address AMR effectively?
This dynamic keynote session will explore key milestones in understanding, preventing, and managing AMR. The discussion will offer the latest insights on where we stand, address what is holding back progress, and showcase successful interventions. In the wake of the United Nations (UN) High-Level Meeting on AMR, this session will also address persistent challenges, including the slow pace of new drug development, inadequate regulatory frameworks, and the need for global coordination.
Ultimately, this session seeks to inspire the World Health Summit (WHS) audience with greater urgency, alignment, and ambition to bring commitments and goals for AMR to fruition from a policy and systems perspective. By examining both achievements and obstacles, this session aims to foster collective action to mitigate AMR's impact on global health. Join us in navigating the complex landscape of AMR, celebrate progress, and address the roadblocks that remain.
Hosts:
Federal Ministry of Health of Germany (BMG)
Moderators:
Latifat Okara
Economist Impact | Principal for Health Policy and Insights | United States of America
Speakers:
Dr. Muna Abu Sin
Federal Ministry of Health (BMG) | Ambassador on Antimicrobial Resistance | Germany
Dr. Abdullah Algwizani
Public Health Authority | CEO | Saudi Arabia
Prof. Dame Sally Davies
UK Special Envoy on Antimicrobial Resistance | United Kingdom
Dr. Arshnee Moodley
CGIAR | Antimicrobial Resistance Hub | Lead | Kenya
Dr. David Reddy
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Director-General | Switzerland
DE 
EN 
